Pyramid Laboratories, Inc. has completed the cGMP manufacturing of Endovasc’s Liprostin for the company’s proposed Phase IIIa trial for patients suffering from Intermittent Claudication. Endovasc’s Liprostin is a liposome-encapsulated form of prostaglandin E-1 (PGE-1), which is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent. In February 2006, Endovasc submitted its protocol for the trial of Liprostin for treatme...